Eujin Park1, Hee Gyung Kang1,2, Young Hun Choi3, Kyoung Bun Lee4, Kyung Chul Moon4,5, Hyeon Joo Jeong6, Michio Nagata7, Hae Il Cheong8,9,10. 1. Department of Pediatrics, Seoul National University Children's Hospital, 101 Daehak-Ro, Jongno-Gu, Seoul, 03080, South Korea. 2. Research Coordination Center for Rare Diseases, Seoul National University Hospital, Seoul, 03080, South Korea. 3. Department of Radiology, Seoul National University College of Medicine, Seoul, 03080, South Korea. 4. Department of Pathology, Seoul National University Hospital, Seoul, 03080, South Korea. 5. Kidney Research Institute, Medical Research Center, Seoul National University College of Medicine, Seoul, 03080, South Korea. 6. Department of Pathology, Yonsei University College of Medicine, Seoul, South Korea. 7. Kidney and Vascular Pathology, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan. 8. Department of Pediatrics, Seoul National University Children's Hospital, 101 Daehak-Ro, Jongno-Gu, Seoul, 03080, South Korea. cheonghi@snu.ac.kr. 9. Research Coordination Center for Rare Diseases, Seoul National University Hospital, Seoul, 03080, South Korea. cheonghi@snu.ac.kr. 10. Kidney Research Institute, Medical Research Center, Seoul National University College of Medicine, Seoul, 03080, South Korea. cheonghi@snu.ac.kr.
Abstract
BACKGROUND: Mutations in the AarF domain containing kinase 4 gene (ADCK4), one of the novel genes causing steroid-resistant nephrotic syndrome (SRNS), usually manifest as isolated adolescent-onset focal segmental glomerulosclerosis (FSGS). ADCK4 interacts with components of the coenzyme Q10 (CoQ10) biosynthesis pathway. METHODS: The incidence and phenotypes of patients with ADCK4 mutations were investigated in a cohort of Korean pediatric patients with SRNS. RESULTS: Among the 53 patients enrolled in the study the incidence of ADCK4-associated FSGS was 7.5% (n = 4) in children aged 5 years and older with multidrug-resistant FSGS. Two additional patients were included for phenotype analyses, one detected by family screening and the other with cyclosporine-responsive FSGS. These six patients presented proteinuria without overt nephrotic syndrome at a median age of 110 (range 60-153) months, of whom five progressed to end-stage renal disease within a median period of 46 (range 36-79) months after onset. Renal biopsies revealed mitochondrial abnormalities in podocytes and tubular cells of all patients. Notably, all patients showed accompanying medullary nephrocalcinosis. None of the patients showed other extrarenal manifestations. CONCLUSIONS: ADCK4 mutations should be considered in older children presenting with steroid resistant FSGS. An early diagnosis of ADCK4 mutations is essential because the condition is treatable with CoQ10 supplementation at an early stage. The association with medullary nephrocalcinosis may be an additional diagnostic indicator.
BACKGROUND: Mutations in the AarF domain containing kinase 4 gene (ADCK4), one of the novel genes causing steroid-resistant nephrotic syndrome (SRNS), usually manifest as isolated adolescent-onset focal segmental glomerulosclerosis (FSGS). ADCK4 interacts with components of the coenzyme Q10 (CoQ10) biosynthesis pathway. METHODS: The incidence and phenotypes of patients with ADCK4 mutations were investigated in a cohort of Korean pediatric patients with SRNS. RESULTS: Among the 53 patients enrolled in the study the incidence of ADCK4-associated FSGS was 7.5% (n = 4) in children aged 5 years and older with multidrug-resistant FSGS. Two additional patients were included for phenotype analyses, one detected by family screening and the other with cyclosporine-responsive FSGS. These six patients presented proteinuria without overt nephrotic syndrome at a median age of 110 (range 60-153) months, of whom five progressed to end-stage renal disease within a median period of 46 (range 36-79) months after onset. Renal biopsies revealed mitochondrial abnormalities in podocytes and tubular cells of all patients. Notably, all patients showed accompanying medullary nephrocalcinosis. None of the patients showed other extrarenal manifestations. CONCLUSIONS:ADCK4 mutations should be considered in older children presenting with steroid resistant FSGS. An early diagnosis of ADCK4 mutations is essential because the condition is treatable with CoQ10 supplementation at an early stage. The association with medullary nephrocalcinosis may be an additional diagnostic indicator.
Authors: Luis Carlos López; Markus Schuelke; Catarina M Quinzii; Tomotake Kanki; Richard J T Rodenburg; Ali Naini; Salvatore Dimauro; Michio Hirano Journal: Am J Hum Genet Date: 2006-10-27 Impact factor: 11.025
Authors: Francesca Diomedi-Camassei; Silvia Di Giandomenico; Filippo M Santorelli; Gianluca Caridi; Fiorella Piemonte; Giovanni Montini; Gian Marco Ghiggeri; Luisa Murer; Laura Barisoni; Anna Pastore; Andrea Onetti Muda; Maria Luisa Valente; Enrico Bertini; Francesco Emma Journal: J Am Soc Nephrol Date: 2007-09-12 Impact factor: 10.121
Authors: Carolin E Sadowski; Svjetlana Lovric; Shazia Ashraf; Werner L Pabst; Heon Yung Gee; Stefan Kohl; Susanne Engelmann; Virginia Vega-Warner; Humphrey Fang; Jan Halbritter; Michael J Somers; Weizhen Tan; Shirlee Shril; Inès Fessi; Richard P Lifton; Detlef Bockenhauer; Sherif El-Desoky; Jameela A Kari; Martin Zenker; Markus J Kemper; Dominik Mueller; Hanan M Fathy; Neveen A Soliman; Friedhelm Hildebrandt Journal: J Am Soc Nephrol Date: 2014-10-27 Impact factor: 10.121
Authors: Jea-Hyun Baek; Ivan G Gomez; Yukihiro Wada; Allie Roach; Don Mahad; Jeremy S Duffield Journal: Am J Pathol Date: 2018-09-28 Impact factor: 4.307
Authors: Eujin Park; Chung Lee; Nayoung K D Kim; Yo Han Ahn; Young Seo Park; Joo Hoon Lee; Seong Heon Kim; Min Hyun Cho; Heeyeon Cho; Kee Hwan Yoo; Jae Il Shin; Hee Gyung Kang; Il-Soo Ha; Woong-Yang Park; Hae Il Cheong Journal: J Clin Med Date: 2020-06-26 Impact factor: 4.241